Expertise

My research is centered on the posttranslational modifications of ubiquitin (UB) and small ubiquitin-like modifier (SUMO) for development of UB and SUMO targeted new anticancer drugs.

My current research effort is focused on the following three projects. The 1st project aim to delineate the ubiquitination pathway for SUMO1 degradation and establish the novel concept that UB-SUMO cross-talk controls cancer growth. The 2nd project is to improve the potency and drug-like features of the hit compound SMIC1 through medical chemistry for its clinical development as a new anticancer drug. The 3rd project is to develop TRAIL and SMIC1 combined treatment of cancers.

Dr. Bellail started her research on ubiquitin posttranslational modification pathways in regulation of cancer cell programed death in human cancer.

Her current research aims to develop SMIC1 as a new anticancer drug for clinical cancer therapy and unveil SMIC1 targeted molecular pathways in human cancer.

Communities
Oncology, Pathology and Laboratory Medicine
Degrees
PhD, Université de Caen Normandie, France, Neuroscience, 2002
MSc, Université de Caen Normandie, France, Biochemistry, 1999
BSC, Université de Caen Normandie, France, Cell Biology, 1998